Molnupiravir

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Molnupiravir or lagevrio (brand name) is a new antiviral drug which has recently undergone clinical trials for COVID-19 treatment,[1] and other uses.[2][3][4]

Theory[edit | edit source]

Molnupiravir was developed specifically to target the Venezuelan equine encephalitis virus (VEEV) but proved effective in early trials against COVID-19 caused by the SARS-CoV-2 virus.[5] Molnupiravir targets the virus by introducing copy errors as it replicates.[6] It breaks down to n-hydroxycytidine (NHC) in the body, and is then metabolised to NHC-TP.[6]

Evidence[edit | edit source]

There is no evidence yet of the use of molnupiravir in patients with ME/CFS.

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Molnupiravir was approved for emergency use in the United Kingdom for mild or moderate COVID-19 in people with at least one risk factor for severe disease during late 2021.[2][4]

Side effects in adults taking molnupiravir for COVID-19 for the recommended 5 days included diarrhea, nausea, dizziness, and headaches which were either mild or moderate, but this was based on a trial of less than 400 people.[6] Based on drug chemistry, interactions with other drugs are not expected.[6]

Costs and availability[edit | edit source]

Molnupiravir is not yet FDA-approved, although approval is likely in 2022. The European Medicines Agency is conducting a rolling review of molnupiravir for COVID-19 and if had been approved by the UK's Medicines and Healthcare products Regulatory Agency.[4][7] Molnupiravir is taken orally.[1][8]

Articles and news[edit | edit source]

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 Mahase, Elisabeth (October 4, 2021). "Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports". BMJ. 375: n2422. doi:10.1136/bmj.n2422. ISSN 1756-1833. PMID 34607801.
  2. ↑ 2.0 2.1 "Molnupiravir". DrugBank. Retrieved October 26, 2021.
  3. ↑ "Molnupiravir FDA Approval Status". Drugs.com. Retrieved October 26, 2021.
  4. ↑ 4.0 4.1 4.2 "First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA". gov.uk. Retrieved November 7, 2021.
  5. ↑ Malek, Rory J.; Bill, Colin A.; Vines, Charlotte M. (December 1, 2021). "Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19". Biomedicine & Pharmacotherapy. 144: 112276. doi:10.1016/j.biopha.2021.112276. ISSN 0753-3322.
  6. ↑ 6.0 6.1 6.2 6.3 "Lagevrio 200 mg hard capsules - Summary of Product Characteristics (SmPC)". Electronic Medicines Compendium. Retrieved November 7, 2021.
  7. ↑ "Covid-19: EMA starts rolling review of molnupiravir". European Medicines Agency. 2021.
  8. ↑ "A Pill to Treat COVID Could Be Just Months Away". WebMD. Retrieved October 26, 2021.

adverse reaction Any unintended or unwanted response to a treatment, whether in a clinical trial or licensed treatment. May be minor or serious.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

Retrieved from "https://me-pedia.org/w/index.php?title=Molnupiravir&oldid=241419"